Research Article
Does HPV Subtype Predict Outcomes in Head and Neck Cancers?
Table 1
Baseline patient and tumor characteristics stratified by HPV status (n = 280).
| | Characteristic | All patients (n = 280) | HPV status | value | | HPV-negative (n = 196) | HPV-16 (n = 75) | HPV-other (n = 9) |
| | Age (years)–mean ± SD | 61.9 ± 11.1 | 62.7 ± 11.1 | 60.8 ± 10.3 | 53.8 ± 13.2 | 0.034 | | Male–n (%) | 217 (77.5) | 148 (75.5) | 61 (81.3) | 8 (88.9) | 0.418 | | T stage–n (%) | | T1 | 20 (7.2) | 12 (6.2) | 8 (10.8) | 0 (0) | 0.113 | | T2 | 96 (34.5) | 61 (31.3) | 31 (41.9) | 4 (44.4) | | T3 | 57 (20.5) | 38 (19.5) | 17 (23.0) | 2 (22.2) | | T4 | 105 (37.8) | 84 (43.1) | 18 (24.3) | 3 (33.3) | | N stage–n (%) | | N0 | 124 (44.4) | 91 (46.4) | 27 (36.5) | 6 (66.7) | 0.221 | | N1 | 42 (15.1) | 24 (12.2) | 17 (23.0) | 1 (11.1) | | N2 | 108 (38.7) | 78 (39.8) | 28 (37.8) | 2 (22.2) | | N3 | 5 (1.8) | 3 (1.5) | 2 (2.7) | 0 (0) | | Overall stage (AJCC 7th edition)–n (%) | | I | 8 (2.9) | 5 (2.6) | 3 (4.1) | 0 (0) | 0.415 | | II | 47 (16.9) | 34 (17.4) | 10 (13.5) | 3 (33.3) | | III | 52 (18.6) | 32 (16.3) | 18 (24.3) | 2 (22.2) | | IV | 172 (61.7) | 125 (63.8) | 43 (58.1) | 4 (44.4) | | Alcohol abuse–n (%) | 110 (39.3) | 83 (42.4) | 24 (32.0) | 3 (33.3) | 0.276 | | Smoking pack-years–mean ± SD | 27.2 ± 26.8 | 27.4 ± 23.2 | 26.2 ± 34.9 | 32.2 ± 26.7 | 0.345 | | Perineural invasion–n (%) | 84 (39.3) | 74 (43.0) | 8 (23.5) | 2 (25.0) | 0.071 | | Extranodal extension–n (%) | 43 (20.3) | 39 (22.8) | 3 (9.1) | 1 (12.5) | 0.171 | | Lymphovascular invasion–n (%) | 54 (26.0) | 44 (26.0) | 9 (29.0) | 1 (12.5) | 0.636 | | Nonsurgical treatment–n (%) | 67 (23.9) | 23 (11.7) | 42 (56.0) | 2 (22.2) | < 0.001 | | Adjuvant treatment–n (%) | 147 (52.5) | 120 (61.2) | 21 (28.0) | 6 (66.7) | < 0.001 | | p16+–positive/number tested (%) | 50/86 (58.1) | 4/34 (11.7) | 41/46 (89.1) | 5/6 (83.3) | < 0.001 |
|
|
HPV, human papillomavirus; numbers in bold indicate values <0.05. |
